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Abstract 
Histological evidence of benign prostatic hyperplasia (BPH) exceeded 50% in men over 50 years of age and rose to 75% as 
men entered the eighth decade. Therapeutic options for BPH generally fall into one of the three categories: watchful waiting, medical 
treatment and surgery. Excluding watchful waiting, the other forms of intervention directed at modifying the physiologic effects of 
BPH with or without directly altering the prostatic mass or its configuration come with varying effectiveness and risk. Botulinum toxin 
(BTX-A) produce inhibition of acethylcholine release at the neuromuscular junction causes paralyzing effects and atrophy of striated 
as well as the smooth muscle fiber. BTX-A also causes inhibitory effects on the ganglionic and post-ganglionic fibres of autonomic 
nervous system inducing diffuse atrophy and apoptosis of nasal and prostate glands. 
Clinical series demonstrates efficacy of BTX-A in alleviating symptoms induced by BPH. Larger randomized clinical trials 
studies are necessary in order to identify the mechanisms by which BTX-A affects the prostate, the ideal dose and the duration of 
effect. BTX-A injected into prostate appears safe and effective. 
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Introduction 
Urinary obstruction as a result of benign prostatic 
disease has probably been recognized to some degree 
since the earliest days of medicine but Riolan probably 
first formalized this association, in the seventeenth 
century [1]. In the mideighteenth century, Morgagni [2] 
provided one of the earliest descriptions of benign 
prostatic hyperplasia (BPH) and enumerated many of the 
potential medical problems attendant to its development. 
More exact recognition of the pathologic process has 
been credited to Virchow in the last quarter of the 
nineteenth century. BPH is a highly prevalent 
nonmalignant enlargement of the prostate related to 
ageing [3-5]. Almost 80 years ago, Randall [6] found that 
histological evidence of definite or probable BPH 
exceeded 50% in men over 50 years of age and rose to 
75% as men entered the eighth decade. On the other 
hand, clinically important mass-producing BPH occurs in 
only about half (40-50%) of men with presumed 
histological BPH and is clinically manifested in about half 
of these [7]. Berry and associates [8] analysis implies that 
BPH is probably initiated before age 30. 
Therapeutic options for lower urinary tract symptoms 
(LUTS) associated with BPH have expanded rapidly in the 
last two decades. These generally fall into one of the 
three categories: watchful waiting, medical treatment and 
surgery (including minimally invasive) [5]. Excluding 
watchful waiting, the other forms of intervention directed 
at modifying the physiologic effects of BPH with or without 
directly altering the prostatic mass or its configuration 
come with varying effectiveness and risk. Thus, there has 
been much interest in the development of alternative 
treatments such as the injection of botulinum toxin type A 
(BTX-A) into the prostate. 
Mechanism of action and preclinical data 
Botulinum toxin (BTX), the most poisonous from all 
poisons, was first identified in 1897 as the product of 
Clostridium botulinum [ 9]. From the seven 
immunologically distinct serotypes of BTX (A,B,C,D,E,F, 
and G) [10], only BTX-A and BTX type B are in clinical 
use [11]. Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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Synthesized as a single-chain, inactive polypeptide 
(protoxin) must be cleaved, in order to be activated into a 
heavy chain, responsible for the specificity of each 
serotype and a light chain, responsible for the 
pharmacological action, connected to one another by a 
disulphide bond and non-covalent interactions. [12-15]. 
Heavy chain provides binding selectively and irreversibly 
to ecto-receptors on the presynaptic motor nerve ending 
followed by internalization, and translocation of the light 
chain into the cytoplasm, the later preventing exocitosis of 
acethylcholine. 
The inhibition of acethylcholine release at the 
neuromuscular junction causes paralyzing effects and 
atrophy of striated as well as the smooth muscle fiber 
[14]. BTX-A also causes inhibitory effects on the 
ganglionic and post-ganglionic fibres of autonomic 
nervous system inducing diffuse atrophy and apoptosis of 
nasal and prostate glands [16-18]. 
The analgesic proprieties of BTX-A results by 
inhibiting neuropepdide release from nociceptive afferent 
C fibres, and a considerable reduction in pain [19-25]. It 
has been shown to inhibit the release of CGRP, 
substance P, glutamate, NGF, and ATP, which are 
mediators of painful sensation. BTX-A injection into rat 
proximal urethral sphincter may have significant inhibitory 
effects on norepinephrine release, conforming to Smith et 
al. [26]. 
Chuang et al. injected 100U Botox® into the canine 
prostate. They observed marked atrophy and diffuse 
apoptosis of glands associated with decreased cell 
proliferation. The effect persisted for at least 3 months 
without any notable side effects [27]. Atrophic changes in 
prostate gland and vacuoles formation in smooth muscle 
cells of stromal tissue, and significantly reduced prostate 
urethral pressure response to IV norepinephrine and 
electrostimulation was also observed by Lin et al. [28]. 
Generalized atrophy of the glands, reduction of the 
total prostate volume (PV) and weight and diffuse 
glandular apoptosis with the TUNEL staining was also 
described by Doggweiler et al. on rat prostates injected 
with varying doses of BTX-A [29]. 
 
 
 
Clinical data 
BPH in humans is a nodular, regional growth with a 
variegated gross appearance resulting from the 
inhomogeneous and irregular mixture of glandular and 
stromal tissue. BPH nodules are almost always located 
centrally in the periurethral portion of the enlarged gland. 
In many instances, the nodular hyperplasia is separated 
by a distinct, smooth, cleavage plane from the 
compressed peripheral prostate that resembles a capsule. 
The weight of the hyperplastic tissue is highly variable, 
ranging from a few grams to more than 200g; no clear 
relationship between the size of the adenoma and the 
degree of bladder neck obstruction has been established. 
Two main factors contribute to symptoms of BPH: 
excessive growth of prostatic tissue (static component) 
under the parasympathetic control and regulated by 
androgen, and increase in smooth muscle tone (dynamic 
component) sympathetically influenced [30]. Contraction 
of the autonomically controlled prostate or bladder neck 
smooth muscle is postulated to be a significant modifiable 
functional component of BPH-mediated bladder neck 
obstruction. BTX-A inhibits acetylcholine release at the 
neuromuscular and neuroglandular junction. BTX-A also 
blocks acetylcholine in the autonomic neurons innervating 
the glandular system resulting in a decreased secretion of 
norepinephrine release [4]. 
Maria  et al. [ 31] published in 2003 the first 
prospective, randomized double-blind, placebo-controlled 
trial in 30 men with BPH (Table 1). The mean follow-up 
period was 19.6 months. Dose consisted in 4ml of 
solution (200U BTX-A). At one month respectively at two 
months evaluation, 11 respectively 13 patients out of 15 
had symptomatic relief, the AUA (American Urological 
Association) score was reduced by 54% (p=0.00001) and 
65% (p=0.00001) and the serum PSA level by 42% 
(p=0.00006), respectively 51%(p=0.00001). PV 
decreased by 54% (p=0.00001) and 68% (p=0.00001) at 
one month respectively at two-months follow-up, and the 
PVR (postvoid residual volume) by 60% (p=0.00001), 
respectively by 83% (p=0.00001) [31].  
 
 
 
Study   PSA(ng/ml  PVR(ml)  PV (ml)  Qmax (ml/s)  QoL  IPSS 
  PI  FU 
Maria et 
al; [31] 
3.7 to 1.8 
51%, 
p=0.00001 
126.3 to 21 
83%, 
p=0.00001 
52.6 to 
16.8 
68%, 
p<0.00001 
8.1 to 15.4  
p<0.00001   
23.2 to 8 
65%, 
p=0.00001
13(15)  2 
Chuang 
et al; 
[18]  
NA 
177.6 to 24.5 
86.2%, 
p=0.064 
61.6 to 50 
18.8%,  
p<0.05 
7..5 to 12.9  
72%, p<0.05 
3.9 to 2.1 
61.5%, 
p<0.05 
From 19 to 
5 
 (73%, 
p<0.05) 
8(8)  1 
Chuang 
et al; 
[32] 
0.8 to 0.72 
NA 
67.7 to 25.1 
63%, NA 
19.6 to 17 
13.3%, 
p<0.0014 
7.3 to 11.8  
39.8%, p<0.001 
3.8 to 2.1 
44.7%, 
p<0.0001 
18.8 to 8.9
52.6%, 
p=0.0001 
16(16)  1 
 
                 
Abbreviations: PI, patients improved, FU, follow-up (months); IPSS, International Prostate Symptoms Score; QoL, quality of 
life; Qmax, maximum urinary flow rate; PV, prostate volume; PVR, post-void residual volume; NA, not available. Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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NA  64.2 to 35.7 
44%, p=0.3 
21.1 to 18 
15%,  
p<0.001 
7.9 to 12 
62%, p<0.001 
3.9 to 2.1 
46%,  
p<0.001 
18.7 to 9.8
48%,  
p<0.001 
100U  1      Chuang 
et al; 
[33] 
 
NA  161.7 to 45.2 
72%, p=0.02 
54.3 to 
46.3 
15%,  
p<0.001 
7 to 10.3  
47%, p<0.001 
4.1 to 2 
51%,  
p<0.001 
19.3 to 9.5
51%, 
p<0.001 
200U 
31(41) 
1 
Kuo; 
[35]   NA  243.5 to 36.8 
p=0.005 
65.5 to 
49.6 
p=0.009 
7.6 to 11.6  
p=0.05 
4.5 to 2.1 
p<0.0001  NA  10(10)  6 
Park et 
al; [36] 
2.6 to 2.4 
NA 
122.7 to 84.7 
34%, p<0.05 
47.2 to 42 
13.1%,  
p<0.05 
9.6 to 11.1 
15.5%, p<0.05  NA 
24.3 to 
16.9 
30.3%, 
p<0.05 
39(52)  3 
Silva et 
al; [34]  
6 to 5 
p=0.04  0 to 92  70 to 47 
p<0.001  0 to 10.3  NA  NA  10(10)  3 
Silva et 
al; [40] 
 
25% 
decrease 
 
55 to 82 
82 to 49 
(6m) then 
73 (18m) 
11.3 to 11.3  NA  10 to 12  11(11)  18         
   
6.2 to 4.8 
p=0.03 
92.1 to 80.3 
P=0.01 
54.1 to 
47.2 
p=0.01 
8.6 to 13.1 
p=0.01   NA 
AUA 24.1 
to 12.6 
p=0.00001
41(77)  1 
6.2 to 3.0  
p=0.00001 
92.1 to 40.6 
p=0.002 
54.1 to 
30.9  
p=0000.1 
8.6 to 16.5    NA  24.1 to 8.7  
P=00001  55(77)  2 
Brisinda 
et 
al ;[41] 
3.0 to 3.1 
p=0.7 
40.6 to 27.1 
p=0.03  
30.9 to 
26.9  
16.5 to 14.5 
p=0.03  NA 
 8.7 to 
11.1 
p=0.02 
55+22(77)  30 
 
Professor Chuang and Professor Chancellor, co-
authors of the present review, pioneers in investigating 
the effects of BTX-A in prostatic tissue, have published 
three studies on the subject. At first they studied the effect 
of BTX-A in BPH on 8 men with symptomatic BPH. PV 
was significantly reduced from 61.6±8.7 to 50.0±5.9 ml 
(18.8%, p<0.05), IPSS score from 19.0±1.8 to 5.1±2.0 
(73.1%, p<0.05), QoL (Quality of Life) index from 3.9±0.3 
to 1.5±0.2 (61.5%, p<0.05) and PVR from 177.6±71.7 to 
24.5±4.5 (86.2%, p=0.06). Qmax increased from 7.5±1.8 
to 12.9±0.5 ml (72%, p<0.05) at one month follow-up [18]. 
They also investigated the therapeutic effect in small 
prostates and reported that BTX-A improves BPH 
symptoms, in 16 patients with PV<30ml [32]. All patients 
reported subjective improvement starting at one week, 
achieved the maximal effect after one month and 
maintained it for a mean follow-up of ten months. The 
mean PV, IPSS score, quality of life index were 
significantly reduced by 13.3% (from 19.6±1.2 ml to 
17.0±1.1ml, p=0.0014), 52.6% (from 18.8±1.6 to 8.9±1.9, 
p<0.0001), and 44.7% (from 3.8±0.3 to 2.1±0.3, 
p<0.0001), respectively. The maximal flow rate was 
significantly increased by 39.8% (7.3±0.7 ml/sec to 
11.8±0.8 ml/sec, p<0.0001) [32]. Chuang et al. also 
treated 41 men with 100U (N=20, for prostates<30 ml) or 
200U (N=20, for prostates>30 ml) of BTX-A [45]. LUTS 
and QoL indices both improved by over 30% in 31 out of 
41 patients (76%). Four out of five men (80%) with urinary 
retention for more than one month could void 
spontaneously after BTX-A injection. Twelve of 41 
patients (29%) did not have change of PV but 7 of these 
men had more than 30% improvement in Qmax, LUTS, 
QoL scores, suggesting that the mechanisms of LUTS 
relief through intraprostatic BTX-A injection may depend 
on the inhibitory effect on the smooth muscle tone and 
sensory nerve function [33]. The efficacy was maintained 
at 12 months.  
Twenty one men (mean age 80±2 years) with BPH, 
on chronic indwelling catheter for at least 3 months, with 
poor general condition received 200U BTX-A in a study 
conducted by Sylva et al. [34]. PV decreased from 
70±10ml to 57±10ml(p<0.0006) at one month and to 
47±7ml (p=0.03 against 1month) at three months.16 
(76%) patients could resume voiding at one month, with a 
mean Qmax of 9.0±1.2 ml/s and PVR of 80±19ml. At 
three months, 17 patients (81%) voided with a mean 
Qmax of 10.3±1.4ml/s and PVR of 92±24ml. PSA 
deceased  at three month from 6.0±1.1ng/ml to 
5.0±0.9ng/ml (p=0.04) [34]. 
Kuo reported injection of BTX-A into transitional zone 
via cystoscopy [35] for benign prostatic obstruction, 
associated with chronic urinary retention or large residual 
urine. All patients had improvement in spontaneous 
voiding with a significant decrease at six months in PVR 
from 243.0±133.9 to 36.8±34.1ml (84.8%, p=0.005), PV 
from 65.6±19 to 49.5±17.6ml (29.9%, p=0.009), QoL 
index from 4.5±2.7to 2.1±1.9 (53.3%, p<0.001) [35]. He 
also reported a decrease in Qmax from 7.6±3.9 to 
11.6±3.5ml/s (p=0.05). The BTX-A effects appeared at 
one week and maintained after a mean follow-up of 9 
months. 
Park et al. reported symptomatic improvement in 39 
out of the 52 patients transperineally injected with 100U to 
300U Botox® [47]. Qmax increased by 15.5%( p<0.05). 
The storage symptoms were improved more than the 
voiding symptoms. IPSS, QoL, PV, and PVR decreased 
by 30.3%(p<0.05), 34.3%, 13.1%( p<0.05) and 34.3% Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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(p<0.05), respectively [36]. The follow-up period was three 
months. 
Guercini et al. and Larson et al. also reported good 
results after treating 16 respectively 10 patients suffering 
from BPH with BTX-A [37, 38]. 
The doses used in intraprostatic injection of BTX-A 
are well below the presumed fatal dose and only minute 
quantities reach the systemic circulation. Dysuria and 
occasional minor hematuria were noted in three patients 
but the symptoms resolved by the next day [44]. Larson et 
al reported one case of acute epidydimitis [38]. The 
procedure is considered safe [39]. 
The longest follow-up data comes from Silva et al, 
who continuing the previous presented study [34] after 18 
months had observed that mean prostate volume at 
baseline, 82 ± 16 ml progressively decreased from month 
one coming to 49 ± 9,5 ml (p = 0,003) at month six, but 
from this moment on, prostate volume slowly recovered, 
becoming identical to baseline at 18 months (73 ± 16 ml, 
p = 0.03).  
They did not observed the same trend in the maximal flow 
which remains relatively constant 11.3 ± 1.7 ml/sec [40]. 
The same favourable results are published also this 
year by Brisinda et al. [41] after injecting 200 UI BTX-A  
into prostate of 77 symptomatic patients. 41 patients had 
subjective symptomatic relief. Compared with baseline 
values, serum PSA was reduced from 6.2 ± 1.7 to 4.8 ± 
1.0 ng/mL (P = .03) and AUA score from 24.1 ± 4.6 to 
12.6 ± 2.9 (P = .00001). At the same time, prostatic 
volume and residual urine volume were reduced by 12.7% 
and 12.8%, respectively, and mean peak urinary flow rate 
increased (P = .01). At 2 months' evaluation, 55 patients 
had subjective symptomatic relief. AUA score was 
reduced by 63.9% (P=0.00001) compared with baseline 
values. In the same patients, serum PSA, prostatic 
volume, and residual urine volume were reduced by 
51.6% (P=0.00001), 42.8% (P=0.00001), and 55.9% 
(P=0.002), respectively, and mean peak urinary flow rate 
increased significantly [41] (Table 1). 
Conclusion 
Clinical series demonstrates efficacy of BTX-A in 
alleviating symptoms induced by BPH. Larger randomized 
clinical trials studies are necessary in order to identify the 
mechanisms by which BTX-A affects the prostate, the 
ideal dose and the duration of effect. 
References 
1.  Gillenwater, Jay Y., Grayhack, 
John T., Howards, Stuart S., 
Mitchell, Michael E.. Adult and 
pediatric urology. Adult & Pediatric 
Urology (4th  Edition).   Lippincott 
Williams & Wilkins, 2002, p1416. 
2.  Morgagni GB. The  seats  and 
causes of disease investigated by 
anatomy,  book 3. London: Johnson 
& Paine, 1760:460. 
3.  Roehrborn CG, Bartsch G, Kirby 
R, et al: Guidelines for the diagnosis 
and treatment of benign prostatic 
hyperplasia: a comparative, 
international overview. Urology 2001; 
58:642-650.  
4.  Chute CG, Panser LA, Girman CJ, 
et al. The prevalence of prostatism: 
a population based survey of urinary 
symptom. J Urol 1993; 150:85-89. 
5.  De la Rosette JJMCH, Alivizatos 
G, Madersbacher S, et al. 
Guidelines on benign prostatic 
hyperplasia. In: European 
Association of Urology guidelines. 
2008 edition. Edited by Aus G, 
Hanus T, Irani J et al. Arnhem: EAU 
Guidelines Office; 2008. pp. 1-7. 
6.  Randall A. Surgical pathology of 
prostatic obstruction. Baltimore: 
Williams and Wilkins, 1931. 
7.  Isaacs JT, Coffey DS. Etiology and 
disease process of benign prostatic 
hyperplasia. Prostate  1989; [Suppl 
2]:33. 
8.  Berry SJ, Coffey DS, Walsh PC, et 
al. The development of human 
benign prostatic hyperplasia  with 
age. J Urol 1984; 132:474. 
9.  Schantz EJ, Johnson EA. 
Botulinum toxin: the story of its 
development for treatment of human 
disease. Perspectives in Biology and 
Medicine. 1997; 40: 317-327.  
10.  Smith C. P., Chancellor, M. B.: 
Emerging Role of botulinum toxin in 
the treatment of voiding dysfunction. 
J Urol. 2004;171:2128-37.  
11.  Ilie CP, Chancellor MB. Perspective 
of Botox for treatment of male lower 
urinary tract symptoms. Curr Opin 
Urol 2009 Ian; 19(1):20-5.  
12.  Dolly JO, Aoki KR. The structure 
and mode of action of different 
botulinum toxins. European Journal 
Neurology. 2006;13(Suppl 4)1-9. 
13.  Gury C. Pharmacological and 
medico-economic considerations. In 
Practical handbook on botulinum 
toxin.2007 Edition. Edited by Ranoux 
D and Gury C. Marseille; Solal 
Editeurs. 2007. pp.13-35. 
14.  Coffey DS and Walsh PC: Clinical 
and experimental studies of benign 
prostatic hyperplasia. Urol Clin North 
Am, 1990;17:461-75. 
15.  Moore AP. General and clinical 
aspects of treatment with botulinum 
toxin . In: AP Moore ed., Botulinum 
Toxin Treatment. Oxford: Blackwell 
Science 1995, pp. 28-53. 
16.  Shaari CM, Sanders I., Wu BL, and 
Biller HF: Rhinorrhea is decreased 
in dogs after nasal application of 
Botulinum toxin. Otolaryngol Head 
Neck Surg, 1995;112:566-71  
17.  Rohrbach S, Olthoff A, Laskawim 
R,  et al: Botulinum toxin type A 
induces apoptosis in nasal glands of 
guinea pigs. Ann Otol Rhinol 
Laryngol.2001;110:1045-50. 
18.  Chuang YC, Chancellor MB.: The 
application of botulinum toxin in the 
prostate. J Urol. 2006;176:2375-82. 
19.  Aoki KR Pharmacology and 
immunology of botulinum toxin 
serotypes. Journal of Neurology 
2001; 248:3-10. 
20.  Argoff CE: A focused review on the 
use of botulinum toxins for 
neuropathic pain.Clinic J Pain. 
2002;18:S177-81. 
21.  Chuang YC, Yoshimura N, Huang 
CC, et al.: Intravesical botulinum 
toxin A administration produces 
analgesia against acetic acid 
induced bladder pain responses in 
rats. J Urol, 2004;172:1529-32. 
22.  Khera M, Somogyi GT, Kiss S, et Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
  342 
© 2009, Carol Davila University Foundation 
al.: Botulinum toxin A inhibits ATP 
release from bladder urothelium after 
chronic spinal cord injury. 
Neurochemistry International, 
2004;45:987-93. 
23.  Cui M, Khanijou S, Rubino J and 
Aoki KR:  Subcutaneous 
administration of botulinum toxin 
type A reduces formalin-induced 
pain.  Pain. 2004;107:125-33. 
24.  Giannantoni A, Di Stasi SM, 
Nardicchi V, et al. Botulinum-A toxin 
injections into the detrusor muscle 
decrease nerve growth factor 
bladder tissue levels in patients with 
neurogenic detrusor overactivity. J 
Urol. 2006;175:2341-4. 
25.  Jabber B, Maher N and DeFazio 
MP: Botulinum toxin a improved 
burning pain and alloying in two 
patients with spinal cord pathology. 
Pain Med. 2003;4:206. 
26.  Smith CP, Franks ME, McNeil BK, 
et al.:  Effect of botulinum toxin A on 
the autonomic nervous system of the 
rat lower urinary tract.  J Urol. 
2003;169:1896-900. 
27.  Chuang YC, Tu CH, Huang CC, Lin 
HJ, Chiang YC, Yoshimura N, 
Chancellor MB. Intraprostatic 
injection of botulinum toxin type-A  
28.  relieves bladder outlet obstruction in 
human and induces prostate 
apoptosis in dogs. BMC Urology 
2006;6:12. 
29.  Lin AT, Yang AH, Chen KK. Effects 
of Botulinum toxin A on the 
contractile function of dog prostate. 
Eur Urol 2007;52:582–9. 
30.  Doggweiler R, Zermann DH, 
Ishigooka M, and Schmidt RA: 
Botox induced prostatic involution. 
Prostate 1998;37:44-50. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31.  Thomas CA, Guercini F, Chuang 
YC, Chancellor MB. Botulinum-A 
toxin: an exciting new treatment 
option for prostatic disease. Int J Clin 
Pract. 2006;60:33-37. 
32.  Maria G, Brisinda G, Civello IM, et 
al. Relief by botulinum toxin of 
voiding dysfunction due to benign 
prostatic hyperplasia:  Results of a 
randomized, placebo-controlled 
study.  Urology, 2003; 62:259-264. 
33.  Chuang YC, Chiang PH, Huang 
CC,  et al.: Botulinum toxin type A 
improves benign prostatic 
hyperplasia symptoms in patients 
with small prostates. Urology. 
2005;66:775-779. 
34.  Chuang YC, Chiang PH, 
Yoshimura N, et al.: Sustained 
beneficial effects of intraprostatic 
Botulinum toxin type A injection on 
lower urinary tract symptoms and 
quality of life in men with benign 
prostatic hyperplasia. BJU Int. 
2006;98:1033-37. 
35.  Silva J, Silva C, Saraiva L, et al. 
Intraprostatic botulinum toxin type A 
injection in patients unfit for surgery 
presenting with refractory urinary 
retention and benign prostatic 
enlargement: Effect on prostate 
volume and micturition resumption. 
Eur Urol 2008;53:153-9. 
36.  Kuo HC: Prostate Botulinum toxin A 
injection- an alternative treatment for 
benign prostatic obstruction in poor 
surgical candidates. 
Urology.2005;65:670-4. 
37.  Park DS, Cho TW, Lee YK, et al.: 
Evaluation of short term clinical 
effects and presumptive mechanism  
of Botulinum toxin type A as a 
treatment modality of benign 
prostatic hyperplasia. Yonsei Med J. 
2006;31;47(5):706-14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38.  Guercini F, Giannantoni A, Bard 
RL, et al.: Intraprostatic botulin toxin 
injection in patients with severe 
benign prostatic hyperplasia a 
multicenter feasibility study. J 
Urol.2005;173: 376- 377 (abstract),  
39.  Larson TR, Scottsdale AZ, 
Huidobro C, Acevedo C: 
Intraprostatic injection of botulinum 
toxin in the treatment of symptomatic 
LUTS, including sequential MRIS for 
accurate changes in size of the 
prostate. J Urol. 2005;173: 376- 377 
(abstract),. 
40.  Oeconomou A, Madersbacher H , 
Kiss G, Berger T, Melekos M, 
Rehder P. Is Botulinum Neurotoxin 
Type A (BoNT-A) a Novel Therapy 
for Lower Urinary Tract Symptoms 
Due to Benign Prostatic 
Enlargement? A Review of the 
Literature, Eur Urol 2008, 
doi:10.1016/j.eururo.2008.06.016. 
41.  Silva J, Pinto R, Carvalho T, 
Botelho F, Silva P, Oliveira R, 
Silva C, Cruz F and Dinis P. 
Intraprostatic Botulinum Toxin Type 
A injection in patients with benign 
prostatic enlargement: duration of 
the effect of a single treatment. BMC 
Urology 2009, 9:9. 
42.  Brisinda G, Cadeddu F, Vanella S, 
Mazzeo P, Marniga G, Maria G. 
Relief by Botulinum Toxin of Lower 
Urinary Tract Symptoms Owing to 
Benign Prostatic Hyperplasia: Early 
and Long-Term Results 
Urology,2009; Volume 73, Issue 1, 
Pages 90-94. 
 
 
 
 
 
 
 
 
 
 
 
 